Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · IEX Real-Time Price · USD
+0.99 (2.03%)
Apr 23, 2024, 1:55 PM EDT - Market open

Company Description

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer.

The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates.

Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Janux Therapeutics, Inc.
Janux Therapeutics logo
Country United States
Founded 2017
IPO Date Jun 11, 2021
Industry Biotechnology
Sector Healthcare
Employees 64
CEO Dr. David Alan Campbell Ph.D.

Contact Details

10955 Vista Sorrento Parkway, Suite 200
San Diego, California 92130
United States
Phone (858) 751-4493
Website januxrx.com

Stock Details

Ticker Symbol JANX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001817713
CUSIP Number 47103J105
ISIN Number US47103J1051
Employer ID 82-2289112
SIC Code 2834

Key Executives

Name Position
Dr. David Alan Campbell Ph.D. President, Chief Executive Officer and Director
Byron Robinson J.D., Ph.D. Chief Strategy Officer
Tighe M. Reardon C.F.A., CPA Acting Chief Financial Officer
Charles M. Winter Chief Technical Officer
Dr. Tommy Diraimondo Ph.D. Chief Scientific Officer
James Pennington General Counsel
Brenda Van Vreeswyk Head of Human Resources
Andy Hollman Meyer Chief Business Officer

Latest SEC Filings

Date Type Title
Mar 8, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 8, 2024 10-K Annual Report
Mar 8, 2024 8-K Current Report
Mar 6, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 4, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 29, 2024 424B5 Filing
Feb 29, 2024 8-K Current Report
Feb 29, 2024 FWP Free Writing Prospectus
Feb 28, 2024 8-K Current Report
Feb 28, 2024 424B5 Filing